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2526alternative to CABG, has long
been an attractive option, the need
for subsequent repeat revasculari-
zation is still a big concern (7).
These shortcomings provided
room to develop a new combined
revascularization procedure.
Hybrid coronary revascularization
(HCR) represents a minimally
invasive alternative strategy that
combines the durability and
survival advantage of LIMA-
LAD grafting with less invasive
PCI to treat non-LAD lesions.
Moreover, with the introduction
of the hybrid operating suite, both
surgical and percutaneous proce-dures could be performed consecutively in the same setting. In
initial experiences, 1-stop HCR has proven to be a safe and
feasible option with acceptable clinical outcomes in selected
patients with multivessel coronary artery disease (8–12).
However, few studies are available on the outcomes of this new
hybrid revascularization strategy versus CABG and PCI.
In this study, we compared midterm clinical outcomes
after 3 procedures in a propensity-matched subset of patients
at Fuwai Hospital. All patients in the 3 groups were strat-
iﬁed by the EuroSCORE (European System for Cardiac
Operative Risk Evaluation score) and the SYNTAX
(Synergy Between Percutaneous Coronary Intervention
With Taxus and Cardiac Surgery) score, 2 typical score
systems for clinical and angiographic variables (7,13–15), to
identify which subgroup of patients got optimal outcomes
from 1-stop HCR.Methods
Patient selection. Inclusion criteria for 1-stop HCR were
as follows: 1) unfavorable LAD for PCI (i.e., chronic total
occlusion, excessive tortuosity, severely diffuse lesion),
unprotected left main coronary artery disease, and non-LAD
lesions were technically feasible for PCI with a drug-eluting
stent (DES); and 2) limitations to traditional CABG, such
as pre-existing organ dysfunction, heavily calciﬁed proximal
aorta, or lack of suitable graft conduits.
Exclusion criteria for 1-stop HCR included left subcla-
vian artery and LIMA stenosis, buried intramyocardial
LAD, need for a concomitant operation (e.g., valve repair or
replacement), overt congestive heart failure, hemodynamic
instability, and other conditions rendering PCI unsuitable
(e.g., fresh thrombus, coronary vessel diameter <1.5 mm).
Since the ﬁrst hybrid operation room was established at
Fuwai Hospital in 2007, a hybrid Heart Team, composed of
2 experienced interventional cardiologists and 2 experienced
cardiac surgeons, had been established in 1 cardiology ward.
If the patient’s data met with these inclusion criteria, the
Heart Team would review the patient’s medical conditionand coronary anatomy, and determine whether both LIMA-
LAD grafting and PCI for non-LAD lesions could be
feasible and reasonable. The ultimate decision regarding
revascularization options was reached only after careful
discussion between the Heart Team and the patient.
From June 2007 to December 2010, 141 consecutive
patients underwent 1-stop HCR with LIMA-LAD graft-
ing and DES to non-LAD lesions at Fuwai Hospital.
During the same period, 5,797 patients underwent isolated
CABG with LIMA-LAD grafting and saphenous grafts to
non-LAD lesions through median sternotomy, and 4,254
patients underwent PCI with DES both for LAD and
non-LAD lesions. Using propensity score matching, 2
separate groups of 141 patients were selected from these 2
cohorts as controls (Fig. 1). Matching criteria included
demographics, comorbidities, and coronary anatomy vari-
ables known to be risk factors for revascularization. This
study had been approved by the institutional review board
of Fuwai Hospital.
Surgical procedure. ONE-STOP HCR. The procedure and
antiplatelet strategy were performed as we described before
(12,16). Brieﬂy, LIMA conduit was harvested as a pedicle
under direct vision through a lower partial ministernotomy,
and the distal anastomosis of in situ LIMA-LAD grafting
was completed with the aid of a stabilizing device (Pilling
Weck Surgical Co., Research Triangle Park, North Carolina).
After closure of the thorax, angiography was immediately
performed to conﬁrm patency of the LIMA-LAD graft and
then PCI was performed on non-LAD lesions through the
femoral artery. Guidewire and stent selection were left to the
discretion of the interventionist. Aspirin 100 mg/day was
continued perioperatively, while clopidogrel was dis-
continued at least 7 days before the operation. A loading
dose of clopidogrel 300 mg was administered via a nasogas-
tric tube after conﬁrmation of LIMA-LAD graft patency.
Unfractionated heparin was then administered again to
obtain an activated clotting time >250 s. Aspirin dosage was
300 mg/day for 1 month and 100 mg/day for lifetime, while
clopidogrel was administered as a maintenance dose at
75 mg/day for 12 months. Glycoprotein IIb/IIIa antagonist
was not used perioperatively.
CABG. All patients received general anesthesia and tracheal
intubation. The choice of off-pump or on-pump coronary
artery bypass for a particular patient was made at the
discretion of qualiﬁed responsible surgeons. For the off-
pump procedure, several standard cardiac positioning tech-
niques and coronary artery stabilizers were adopted (17). For
the on-pump procedure, standard cardiopulmonary bypass
techniques were used that incorporated cold antegrade and
retrograde blood cardioplegia and moderate systemic hypo-
thermia. Apart from differences in surgical procedures, all
other aspects of in-hospital management were done similarly
according to standard protocols in this institute.
PCI. For multivessel coronary artery disease, PCI was per-
formed according to current practice guidelines. Insertion of
Figure 1 Flowchart of the Study Design
CABG ¼ coronary artery bypass grafting; DES ¼ drug-eluting stent(s); EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation score; HCR ¼ hybrid coronary
revascularization; MACCE ¼ major adverse cardiac or cerebrovascular event(s); PCI ¼ percutaneous coronary intervention; SYNTAX ¼ Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery.
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2527DES was performed with an attempt to fully cover the
diseased segment and to ensure complete stent apposition.
The choice of the speciﬁc type of DES was left to the in-
terventionist’s discretion. All patients undergoing PCI were
prescribed aspirin plus clopidogrel (loading dose, 300 mg)
before or during the coronary intervention. After the pro-
cedure, all patients were on continuous aspirin therapy
(300 mg/day for 1 month and then switching to 100 mg/day
for lifetime) and clopidogrel 75 mg/day was prescribed for
6 to 12 months following implantation of DES.
Calculation of scores and stratiﬁcation. Demographic and
clinical data were retrospectively collected on a dedicated
database. EuroSCORE was calculated on the basis of the
original methodology (13). Coronary angiograms were
analyzed by an independent angiographic core lab (CCRF,
Beijing, China) by experienced technicians. Diagnostic
angiograms were scored, according to the SYNTAX score
algorithm (15). EuroSCORE cutoffs (low, 2; medium, >2
and <6; high, 6) were identiﬁed by consensus. Subgroups
of the SYNTAX score were identiﬁed by tertiles (low, 24;
medium, >24 and <30; high, 30).
Study endpoints and follow-up. The primary endpoint
during follow-up was the incidence of major adverse cardiac
or cerebrovascular events (MACCE), a composite of death,
myocardial infarction (classical symptoms, electrocardiogramand serum cardiac biomarkers changes), neurologic event
(stroke or transient ischemic attack), and target lesion or
vessel repeat revascularization.
As part of institutional standard procedures, all surgical
and interventional patients were required to return for an
outpatient follow-up visit at 6 months after discharged
from the hospital and then once every year. Holter, chest
X-ray, and ultrasonic cardiography were set as routine
programs. Myocardial perfusion imaging was recom-
mended for patients without ischemic symptoms. Angi-
ography would be performed if noninvasive diagnostic tests
indicated the sign of ischemia. Both myocardial perfusion
and angiography were strongly recommended for patients
with the recurrence of ischemic symptoms. Hospital data-
bases were checked annually to identify and review any
routine follow-up information. In addition, all participants
in the present study were contacted by telephone or mail
again by the research staff using standard procedures and
forms.
Statistics. A multivariate logistic regression model was
used to develop a propensity score for each patient. All
prespeciﬁed covariates were listed in Table 1. Nearest-
neighbor propensity score matching was subsequently
used to match patients in the 1-stop HCR group with those
in the CABG and PCI cohorts. Continuous variables were
Table 2
Procedural Characteristics of Patients in the
Hybrid Group
Bypassed LIMA-LAD 141/141 (100%)
Stented patients 141/141 (100%)
Stented lesion 213
LM 16
Diagonal artery 14
LCX 69
RCA 114
Number of stents 271
Number of sirolimus-eluting stents 210
Number of paclitaxel-eluting stents 8
Number of Endeavor zotarolimus-eluting stents 12
Number of Resolute zotarolimus-eluting stents 41
Total stent length per patient, mm 32.6  15.1
Values are n/N (%), n, or mean  SD.
LIMA ¼ left internal mammary artery; other abbreviations as in Table 1.
Table 1 Demographic and Clinical Baseline Characteristics
Hybrid
(n ¼ 141)
CABG
(n ¼ 141)
PCI
(n ¼ 141) p Value
Age, yrs 62.0  9.9 62.4  7.8 61.7  10.3 0.977
Male 88.7% 90.1% 87.23% 0.754
BMI, kg/m2 25.8  2.8 25.4  2.8 25.7  2.7 0.463
Smoker 55.3% 66.0% 24.8% <0.001
Diabetes mellitus 26.2% 18.4% 19.9% 0.236
Hypercholesterolemia 53.2% 55.3% 48.9% 0.550
Hypertension 64.5% 65.2% 59.6% 0.561
Renal dysfunction 2.8% 3.5% 5.0% 0.635
Previous cerebrovascular accident 10.6% 12.1% 19.1% 0.087
COPD 7.1% 8.5% 7.8% 0.906
Peripheral arterial disease 24.1% 25.5% 29.1% 0.621
Previous MI 27.7% 31.2% 27.7% 0.750
LVEF, % 62.7  7.1 62.6  8.0 61.2  9.3 0.508
Previous PCI 9.2% 7.8% 14.2% 0.183
SYNTAX score 27.6  7.9 28.2  9.4 26.0  8.2 0.060
EuroSCORE 3.1  2.3 3.3  2.3 3.5  2.6 0.655
LM 19.90% 22.7% 15.6% 0.317
LAD 100% 100% 100% 1.000
LCX 65.2% 75.9% 72.3% 0.133
RCA 75.2% 83.7% 77.3% 0.192
Values are mean  SD or %.
BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation
score; LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex artery; LM ¼ left main coronary artery disease; LVEF ¼ left ventricular
ejection fraction; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; SYNTAX ¼ Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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2528expressed as mean  SD, and categorical variables as
frequencies and percentages. Categorical variables
were compared using the chi-square statistic between groups.
If continuous variables were normally distributed
and variance was homogeneic, then they would be analyzed
by 1-way analysis of variance. Otherwise, they would be
analyzed by Kruskal-Wallis test. Kaplan-Meier methodology
was used to compare cumulative MACCE rates between
groups. A p value <0.05 was considered statistically signiﬁ-
cant. All statistical analysis was performed using the SPSS
software package for Windows version 17.0 (SPSS Inc.,
Chicago, Illinois).
Results
Patient characteristics. After propensity score matching,
baseline characteristics were similar in the 3 groups
(Table 1). In the hybrid group, all patients received
a LIMA-LAD graft and PCI with DES for non-LAD
lesions, the mean number of stents implanted in a patient
was 1.9, and the mean total length of the stents was 32.6 
15.1 mm (Table 2).
In the CABG group, 29 patients (20.6%) underwent off-
pump surgery. All patients received a LIMA-LAD graft.
Additionally, the CABG group received 289 saphenous vein
grafts in non-LAD targets. The mean number of grafts was
3.0 (Table 3).
In the PCI group, the mean number of stents implanted
in a patient was 2.7 (1.5 for non-LAD and 1.2 for LAD).
The mean total length of the stents was 62.8 mm (32.5 mmfor non-LAD and 30.3 mm for LAD) (Table 4).
Considering the complexity of coronary anatomy, 6 patients
underwent staged procedures. The types of stents in the
hybrid and PCI groups included the Cypher sirolimus-
eluting stents (Cordis, Johnson & Johnson, Warren, New
Jersey, Bridgewater, New Jersey), Taxus paclitaxel-eluting
stents (Boston Scientiﬁc, Natick, Massachusetts), and
Endeavor and Resolute zotarolimus-eluting stents (Med-
tronic, Minneapolis, Minnesota).
Midterm outcomes. By March 2012, follow-up infor-
mation and hospital records review were 100% complete.
At a mean follow-up of 3 years, actuarial survival rates in
Table 3 Procedural Characteristics for Patients in CABG Group
Bypassed LIMA-LAD 141/141 (100%)
Saphenous vein 289
DA 56
LCX 15
OM 78
RCA 31
PDA 72
LVB 37
Number of distal anastomoses 3.0  0.7
Values are n/N (%), n, or mean  SD.
DA ¼ diagonal artery; LVB ¼ left ventricular branch; OM ¼ obtuse marginal; PDA ¼ posterior
descending artery; other abbreviations as in Table 1.
Table 5 MACCE in the Hybrid, CABG, and PCI Groups
Hybrid CABG PCI p Value
Death 1 4 5 0.344
Myocardial infarction 0 3 6 0.062
Neurologic event 2 9 3 0.083
Repeat revascularization 6 3 18 <0.001
Any MACCE 9 19 32 0.003
Follow-up time, mean, yrs 2.9 3.2 3.0
Values are numbers of events unless otherwise noted. n ¼ 141 per group.
MACCE ¼ major adverse cardiac or cerebrovascular event(s); other abbreviations as in
Table 1.
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2529the hybrid, CABG, and PCI groups were 99.3%, 97.2%,
and 96.5%, respectively (log-rank p ¼ 0.344). Six patients
in the hybrid group, 3 patients in the CABG group, and
18 patients in the PCI group underwent repeat revascu-
larization (Table 5).
Compared with the hybrid group, repeat revascularization
in the PCI group was mainly concentrated in the LAD (2
vs. 10; p ¼ 0.029), and PCI with DES for non-LAD
offered a similar repeat revascularization rate in the hybrid
and PCI groups (4 vs. 8; p ¼ 0.307) (Table 6). The
cumulative MACCE rate in the hybrid group (6.4%) was
signiﬁcantly lower than that in the PCI group (22.7%;
p < 0.001), but similar to that in the CABG group (13.5%;
p ¼ 0.140) (Fig. 2). Overall, 61 patients (43.3%) in the
hybrid group, 54 patients (38.3%) in the CABG group, and
63 patients (44.7%) in the PCI group underwent coronary
angiography during follow-up.
Stratiﬁcation by EuroSCORE. In the low and medium
EuroSCORE tertiles, the MACCE rate in the hybrid group
did not differ signiﬁcantly with those in the CABG (p ¼
0.959 and p ¼ 0.914, respectively) and PCI groups (p ¼
0.352 and p ¼ 0.172, respectively). But in the high Euro-
SCORE tertile, the MACCE rate in the hybrid group was
signiﬁcantly lower than in the CABG (p ¼ 0.030) and PCI
groups (p ¼ 0.006) (Table 7, Fig. 3).Table 4
Procedural Characteristics of Patients in the
PCI Group
Stented patients 141/141 (100%)
Stented lesion 342
LM 13
LAD 152
LCX 81
RCA 96
Number of stents 383
Number of sirolimus-eluting stents 231
Number of paclitaxel-eluting stents 5
Number of Endeavor zotarolimus-eluting stents 42
Number of Resolute zotarolimus-eluting stents 105
Total stent length per patient, mm 62.8  29.1
Values are n/N (%), n, or mean  SD.
Abbreviations as in Table 1.Stratiﬁcation by SYNTAX score. In the low and medium
SYNTAX score tertiles, the MACCE rate in the hybrid
group was not statistically different from those in the CABG
(p ¼ 0.703 and p ¼ 0.254, respectively) and PCI groups
(p ¼ 0.224 and p¼ 0.114, respectively). Patients with a high
SYNTAX score who underwent 1-stop HCR had a lower
MACCE rate than that in the PCI group (p ¼ 0.002), but
similar to that in the CABG group (p ¼ 0.362) (Table 8,
Fig. 4).Discussion
To our knowledge, this is by far the largest series of
1-stop HCR with the longest follow-up. The concept of
HCR, ﬁrst introduced by Angelini and colleagues in 1996
(18), is based on combining the excellent long-term
patency of the LIMA-LAD graft by surgical procedure
and minimal invasiveness of interventional procedures to
achieve complete revascularization. Compared with the
staged procedures, 1-stop HCR eliminated logistic con-
cerns about the timing or sequencing of separate proce-
dures and minimized the inconvenience of transferring
patients and exposure to anesthesia. Especially when PCI
complication or failure occurs, CABG can be performed
immediately. And in the setting of coronary artery disease,
both clinical variables and angiographic information are
important in deﬁning the risk of patients undergoing
revascularization (15,19,20). Therefore we chose typical
clinical and angiographic scoring systems, EuroSCORE
and SYNTAX score, to stratify patients undergoingTable 6
The Location of the Repeat Revascularization
Performed in Hybrid, CABG, and PCI Groups
Hybrid PCI CABG
LAD 2 10 2
Target lesion 6
Nontarget lesion 4
Non-LAD 4 8 1
Target lesion 1 1
Nontarget lesion 3 7
n ¼ 141 per group. In the hybrid group, 1 patient each underwent repeat revascularization for
LIMA graft occlusion and LAD de novo lesion. In the CABG group, 2 patients underwent repeat
revascularization for LIMA graft occlusion and 1 patient for saphenous vein grafts occlusion.
Abbreviations as in Tables 1 and 2.
Figure 2
The Cumulative MACCE Rate in Hybrid, CABG, and
PCI Groups
The cumulative MACCE rate in the hybrid group (6.4%) was signiﬁcantly lower than
that in the PCI group (22.7%; p < 0.001), but similar to that in the CABG group
(13.5%; p ¼ 0.140). Abbreviations as in Figure 1.
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2530revascularization into 3 different risk levels; then midterm
outcomes in each subgroup were compared between 1-stop
HCR and conventional revascularization strategies.
Hybrid versus CABG. Compared to CABG, the advan-
tages of 1-stop HCR lie in the following. First, LIMA-LAD
graft quality was further conﬁrmed by instant angiogra-
phy and any deﬁciency could be corrected immediately.
Combining the tools of the catheterization laboratory and
operating room greatly enhanced the options available toTable 7
MACCE in Hybrid, CABG, and PCI Groups From
Low to High EuroSCORE Tertile
Hybrid CABG PCI p Value
Low n ¼ 60 n ¼ 58 n ¼ 53
Death 0 0 0
Myocardial infarction 0 0 2 0.143
Neurologic event 1 2 0 0.389
Repeat revascularization 1 0 3 0.167
Any MACCE 2 2 5 0.336
Medium n ¼ 52 n ¼ 50 n ¼ 53
Death 1 2 1 0.829
Myocardial infarction 0 0 2 0.154
Neurologic event 0 1 1 0.641
Repeat revascularization 4 2 7 0.259
Any MACCE 5 5 11 0.206
High n ¼ 29 n ¼ 33 n ¼ 35
Death 0 2 4 0.214
Myocardial infarction 0 3 2 0.290
Neurologic event 1 6 2 0.163
Repeat revascularization 1 1 8 0.015
Any MACCE 2 12 16 0.030
Abbreviations as in Tables 1 and 5.surgeons and changed surgeons’ behavior by providing
instant feedback on issues that were difﬁcult to evaluate with
the naked eye (21–24). In hybrid group, 4 major defects
were found in LIMA-LAD grafts after intraoperative
angiography, 2 in the LIMA conduit and 2 at the distal
anastomosis. All 4 of the defects were surgically corrected by
immediate reoperation. Zhao et al. (24) also reported that
7% of angiographic defects in LIMA-LAD grafts were
identiﬁed after intraoperative angiography, which may have
otherwise been missed.
Second is the avoidance of aortic manipulation, 1 of
the unique characteristics of the hybrid technique. Aortic
clamping, a predictor of postoperative cerebral infarction, is
still required during both on-pump and off-pump bypass
surgeries (25). Avoiding aortic manipulation can provide
superior neurologic outcomes irrespective of aortic screening
strategy or severity of atherosclerotic disease (26,27). In
the present study, the incidence of neurologic events in
the hybrid and CABG groups showed no statistical differ-
ence (p ¼ 0.056) (Fig. 5), but the observed trend and
the numerical difference was quite remarkable (1.4%
vs. 6.4%).
Third is the minimal invasiveness. The lesser invasiveness
of HCR could offer superior perioperative outcomes,
including reduced lengths of intubation and ICU stay, and
less transfusion than CABG (9,12). Meanwhile, through
minimally invasive CABG for LAD and PCI for non-LAD
lesions, HCR provided a feasible option to some clinically
high-risk patients who were unable to tolerate median
sternotomy, extracorporeal circulation, or heart rotation
during off-pump CABG. Some other retrospective series
also found that HCR was safe and reliable in select clinically
high-risk patients, with low mortality and morbidity rates
(28–30). Furthermore, compared with bare-metal stents,
DESs signiﬁcantly reduced the restenosis rate, which was
similar to or lower than the failure rate of saphenous grafts
(3–6,31,32). Therefore, combining the LIMA-LAD graft
with DES on the remaining lesions appeared to be a valid
alternative to conventional CABG in select patients. Our
midterm results showed that 1-stop HCR also had a rela-
tively low revascularization rate that was similar to that in
the CABG group (4.3% vs. 2.1%; p ¼ 0.244). Longer
follow-up time and larger sample sizes are necessary to
validate this ﬁnding.
Hybrid versus PCI. Compared with PCI, the main
difference of 1-stop HCR lies in the LIMA-LAD graft.
The primary objective of HCR in the present study was to
cover patients with LAD chronic total occlusion, excessive
tortuosity, severely diffuse lesion, and unprotected left main
artery. It has been conﬁrmed than the complexity of the
coronary lesion directly affects the outcomes of PCI, espe-
cially the need for repeat revascularization, while the success
of grafting is primarily related to the quality of the distal
targets, not the lesions themselves (7). As shown in Table 6,
repeat revascularization in the PCI group was mainly
concentrated in the LAD, while PCI with DES for non-
Figure 3 The Cumulative MACCE Rate in the Hybrid, CABG, and PCI Groups From Low to High EuroSCORE Tertile
In the low and medium European System for Cardiac Operative Risk Evaluation score (EuroSCORE) tertiles, the 1-stop HCR group had a MACCE rate similar to those in the CABG
(p ¼ 0.959 and p ¼ 0.914, respectively) and PCI groups (p ¼ 0.352 and p ¼ 0.172, respectively). In the high EuroSCORE tertile, the MACCE rate in the hybrid group was
signiﬁcantly lower than those in the CABG (p ¼ 0.030) and PCI groups (p ¼ 0.006). Abbreviations as in Figure 1.
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2531LAD offered relatively low and similar repeat revasculari-
zation rates in both the hybrid and PCI groups. Therefore,
for multivessel coronary disease with complex LAD lesions,
grafting LAD with LIMA combined PCI for the remaining
lesions might be a potentially ideal alternative to conven-
tional revascularization strategies. In addition, the chal-
lenging percutaneous procedure of unprotected left main
coronary artery disease could be converted to a more
straightforward one, with myocardial protection provided by
patent LIMA-LAD graft (33,34).
Meanwhile, the minimal invasiveness of PCI makes it
a favorable revascularization strategy for patients with clin-
ically high-risk characteristics that predict an increased rateTable 8
MACCE in Hybrid, CABG, and PCI Groups From
Low to High SYNTAX Score Tertile
Hybrid CABG PCI p Value
Low n ¼ 42 n ¼ 45 n ¼ 55
Death 0 2 1 0.522
Myocardial infarction 0 1 2 0.554
Neurologic event 0 1 2 0.503
Repeat revascularization 2 1 2 0.740
Any MACCE 2 5 7 0.618
Medium n ¼ 47 n ¼ 40 n ¼ 46
Death 1 1 1 1.000
Myocardial infarction 0 0 1 0.437
Neurologic event 1 4 1 0.180
Repeat revascularization 1 1 6 0.073
Any MACCE 3 6 9 0.291
High n ¼ 52 n ¼ 56 n ¼ 40
Death 0 1 3 0.086
Myocardial infarction 0 2 3 0.157
Neurologic event 1 4 0 0.133
Repeat revascularization 3 1 10 <0.001
Any MACCE 4 8 16 0.002
Abbreviations as in Tables 1 and 5.of adverse surgical outcomes. Considering that the superior
longevity of LIMA-LAD graft had a signiﬁcantly positive
impact on long-term survival, especially in certain patients
with clinical risk factors (e.g., advanced age, diabetes, renal
insufﬁciency, and impaired ventricular function) (35–37),
the hybrid revascularization procedure, which combined
minimally invasive CABG for LAD and PCI for non-LAD
lesions, may provide a safe and feasible alternative to PCI for
these patients. In the present study, both PCI and 1-stop
HCR offered relatively low cumulative MACCE rates in
patients with a high EuroSCORE.
Patient selection and heart team approach. As suggested
in the 2011 American College of Cardiology Foundation/
American Heart Association Guideline for PCI, hybrid
revascularization is ideal in patients in whom technical or
anatomic limitations to CABG or PCI alone may be present
and for whom minimizing the invasiveness (and therefore
the risk of morbidity and mortality) of surgical intervention
is preferred (38). Patient selection based on the heart team’s
approach is the key point in whether the HCR strategy
could offer favorable outcomes for patients with multivessel
disease. The heart team should review the patient’s medical
condition and coronary anatomy, determine that PCI for
non-LAD and grafting LAD with LIMA are both tech-
nically feasible and reasonable, and discuss revascularization
options with the patient before the HCR strategy is ﬁnally
selected.
Study limitations. First, this study was based on the
retrospective design; thus, patient selection bias might exist.
Second, hybrid operating rooms are available only in some
large medical centers. Patients for 1-stop HCR were also
carefully selected, and its performance required close col-
laboration of the experienced surgeons and cardiologists, so
our results should be interpreted as effects of the heart team
approach and therefore used with caution in generalizing
Figure 4 The Cumulative MACCE Rate in Hybrid, CABG, and PCI Groups From Low to High SYNTAX Score Tertile
In the low and medium SYNTAX score tertiles, the MACCE rate in hybrid group was similar to those in the CABG (p ¼ 0.703 and p ¼ 0.254, respectively) and PCI groups (p ¼
0.224 and p ¼ 0.114, respectively). In the high SYNTAX tertile, 1-stop HCR had lower MACCE rate than that with PCI (p ¼ 0.002), but similar to that with CABG (p ¼ 0.362).
Abbreviations as in Figure 1.
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2532these results to a broader population of patients with mul-
tivessel coronary artery disease. Third was its relatively small
sample size. Long-term follow-up and randomized studies
comparing 1-stop HCR with conventional revascularization
strategies are warranted.
Conclusions
One-stop HCR provides favorable outcomes for selected
patients with multivessel coronary artery diseases in dif-
ferent risk strata. For patients with a high EuroSCORE orFigure 5
The Incidence of Neurological Events in the Hybrid,
CABG, and PCI Groups
The incidence of neurological events in CABG group did not get signiﬁcant
statistical differences with hybrid group during follow-up (0.7% vs. 2.8%;
p ¼ 0.056). Abbreviations as in Figure 1.SYNTAX score, it may provide a promising alternative
to conventional CABG and PCI. These favorable prelim-
inary ﬁndings warrant further investigation of this hybrid
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